Date: 2013-11-05
Type of information: Licensing agreement
Compound: human antibodies directed to an undisclosed target expressed on the surface of various types of cancers
Company: ADC Therapeutics (Switzerland) Five Prime Therapeutics (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: * On November 5, 2013, ADC Therapeutics, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), and Five Prime Therapeutics, a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, have announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.
Under the agreement, ADC Therapeutics plans to initiate preclinical research and development of antibody-drug conjugates using the antibodies licensed from Five Prime immediately, adding to ADC Therapeutics’ portfolio of proprietary ADC programs. ADC Therapeutics’ unique platform combines monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As ADC Therapeutics’ PBD-based chemistries do not distort the structure of the DNA they give the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market.
Financial terms: Financial terms were not disclosed and remain confidential.
Latest news:
